Devasis Chatterjee, PhD
Assistant Professor of Medicine
Devasis Chatterjee, PhD is assistant professor of medicine at the Warren Alpert Medical School of Brown University and a member of the division of mMedical oncology at Rhode Island Hospital. He received his doctoral training in the section of biochemical pharmacology at Brown University’s division of biology and medicine. He completed postdoctoral training in the department of cancer pharmacology at the Dana Farber Cancer Institute and in the department of molecular and cell biology at Brown University.
Chatterjee moved to Rhode Island Hospital in 2002 to continue his research on the development of novel experimental therapeutics. Work in his laboratory has focused on, mechanism(s) of drug resistance involving dysregulation of apoptosis and cell survival signaling pathways. Specifically, Chatterjee has focused on the regulation of two proteins that directly affect tumor cell death (RKIP) and survival (STAT3). Studies from the Chatterjee lab have uncovered that RKIP is a negative regulator of STAT3-mediated cell survival. Ongoing research supported by COBRE is validating if RKIP is a candidate to be utilized as the basis for molecular-targeted therapeutic strategy for colon cancer.
Selected Publications
Darnowski, J.W., Goulette, F.A., Guan, Y., Chatterjee, D., Cousens. L.P. and Chin, Y.E. STAT3 cleavage by caspases: Impact on full-length STAT3 expression, fragment formation and transcriptional activity. J. Biol. Chem., 281, 17707-17, 2006.
Chatterjee, D.,* Sabo, E., and Resnick, M.B. The prognostic role of RKIP and STAT3 in gastric adenocarcinoma.* Corresponding author. Submitted to Clin. Cancer Res., April 2007.
Baritaki, S., Chatterjee,D., Katsman, A., Yeung,K.C., Spandidos, D.C., and Bonavida, B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor RKIP via YY1 inhibition and DR5 up-regulation. Accepted with minor revisions J. Immunol., May 2007.
Chatterjee, D., Sabo, E, Resnick, M.B. Yeung, K.C. and Chin Y.C. The roles of RKIP and STAT3 in cancer chemotherapy: Opposites Attract. To be Published in:: Sensitization of Cancer Cells for Chemo/Immuno/Radiotherapy. B. Teicher editor, Humana Press. 2007.
Chatterjee, D.,* Yuan, Z., Paisano, C., Darnowski, J., and Chin, E. RKIP and CPT negatively regulate STAT3 activation in human cancer cells. * Corresponding author. In preparation.
|
